Laparoscopic Sentinel Node Navigation Surgery for Gastric Cancer
SNNS
1 other identifier
interventional
101
1 country
1
Brief Summary
There are few reports on a dual dye and isotope approach using laparoscopy in gastric cancer sentinel node mapping. The aim of this study was to evaluate the feasibility of laparoscopic limited gastrectomy with sentinel basin(SB) dissection for gastric cancer using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2 gastric-cancer
Started Jul 2010
Longer than P75 for phase_2 gastric-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2010
CompletedFirst Submitted
Initial submission to the registry
September 25, 2011
CompletedFirst Posted
Study publicly available on registry
September 27, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2016
CompletedJanuary 9, 2017
January 1, 2017
3.1 years
September 25, 2011
January 6, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
3 Year disease free survival
Recurrence evaluation by eddoscopy, computed tomography and Positron emission tomography if needed.
Postoperative 3 year
Secondary Outcomes (1)
Sentinel node detection rate, occurrence of complication ,Qualtity of life and remnant stomach function evaluation.
postoperative 1, 3, 6, 12 month
Study Arms (1)
Laparoscopic sentinel node navigation surgery
EXPERIMENTALLaparoscopic sentinel node navigation surgery
Interventions
Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
Eligibility Criteria
You may qualify if:
- Age 20-80
- Informed consent
- No other malignancies
- cT1N0 stage gastric cancers \< 4cm
- no allergic history of isotope
You may not qualify if:
- Patients eligible for endoscopic submucosal dissection(ESD) with absolute indication
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hyung-Ho Kim, M.D.Ph.D.
Seoul National University Bundang Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
September 25, 2011
First Posted
September 27, 2011
Study Start
July 1, 2010
Primary Completion
August 1, 2013
Study Completion
August 1, 2016
Last Updated
January 9, 2017
Record last verified: 2017-01
Data Sharing
- IPD Sharing
- Will not share